PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

24.10.2023 - Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST ... Seite 1

Related Keywords

France ,Paris ,France General ,French ,Henri Mondor ,Bichat Claude Bernard ,University Hospital Of Nancy ,University Hospital Of Nantes ,Health Products ,Ethics Committee ,South East Ethics Committee Comit ,French National Agency ,Lyon Ethics Committee ,Lyon Ethics ,University Hospital ,Phaxiam Therapeutics Chart ,Haxiam Therapeutics Kurs ,Haxiam Therapeutics Aktie ,